𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus

✍ Scribed by Ng, K. P. ;Manson, J. J. ;Rahman, A. ;Isenberg, D. A.

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
75 KB
Volume
55
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Objective

To identify the prevalence of serologically active clinically quiescent (SACQ) patients in a cohort of 290 patients with systemic lupus erythematosus (SLE). We investigated if the presence of anti–double‐stranded DNA (anti‐dsDNA) or antinucleosome (anti‐NCS) antibodies during the SACQ period was associated with future flares.

Methods

SACQ patients defined as clinically inactive for 6 months (global British Isles Lupus Activity Group index [BILAG] scores <6) and serologically active (anti‐dsDNA antibodies >50 units/ml on at least 2 occasions by enzyme‐linked immunosorbent assay [ELISA]) were identified. Patient sera collected during the defined SACQ period were also tested for anti‐NCS antibodies (ELISA). We retrospectively reviewed patient clinical details and episodes of flare using the BILAG activity index.

Results

Twenty‐seven (9%) patients were SACQ. Seventeen (81%) patients experienced a flare (total of 91 flares, up to 12 flares per person) in the next 5 years. Median duration to first flare was 15 months (range 2–46). Time to first flare after SACQ period was significantly correlated with the presence of anti‐NCS (P = 0.0012), high anti‐NCS antibody titers (P = 0.0006), and anti‐dsDNA titers 5 times above the normal limit (P = 0.02). Patients with higher absolute anti‐NCS antibody titers showed a significant correlation with the number of flares (r = 0.57, P = 0.007).

Conclusion

A minority of patients with SLE are SACQ. The majority of these patients experience a flare in the next 5 years and close followup is recommended. Anti‐NCS antibodies may be a better predictor than anti‐dsDNA antibodies for future flares.

📜 SIMILAR VOLUMES

Clinical significance of anti-annexin V
Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus
✍ Kaburaki, Junichi; Kuwana, Masataka; Yamamoto, Mihoko; Kawai, Shinichi; Ikeda, Y 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

Annexin V has a calcium-dependent binding affinity for anionic phospholipids and activated platelets, and prevents prothrombinase activity. We investigated the clinical significance of IgG anti-annexin V antibodies in patients with SLE. The study population consisted of 140 patients with SLE. Sera w

Systemic lupus erythematosus in a multie
Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: Association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual
✍ Vilá, Luis M. ;Alarcón, Graciela S. ;McGwin, Gerald ;Bastian, Holly M. ;Fessler, 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 1 views

## Abstract ## Objective To determine if lymphopenia is associated with clinical/immunologic manifestations, disease activity, and disease damage in systemic lupus erythematosus (SLE). ## Methods The study group comprised 591 patients with SLE participating in a multiethnic, longitudinal outcome

Activation of the interferon-α pathway i
Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease
✍ Kyriakos A. Kirou; Christina Lee; Sandhya George; Kyriakos Louca; Margaret G. E. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB

## Abstract ## Objective Gene‐expression studies have demonstrated increased expression of interferon (IFN)–inducible genes (IFIGs) in peripheral blood mononuclear cells (PBMCs) of many patients with systemic lupus erythematosus (SLE), with a predominant effect of type I IFN. This study examined t

Antibodies to apolipoprotein A-I, high-d
Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus
✍ Sean G. O'Neill; Ian Giles; Anastasia Lambrianides; Jessica Manson; David D'Cruz 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

## Abstract ## Objective Inflammatory disease activity in patients with systemic lupus erythematosus (SLE) may affect the development of atherosclerosis, contributing to their increased risk of cardiovascular disease (CVD). This process may be mediated by anti–apolipoprotein A‐I (anti–Apo A‐I), an